Cargando…

Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy

Detalles Bibliográficos
Autores principales:	Pettengell, R., Schwenkglenks, M., Bosly, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275304/ https://www.ncbi.nlm.nih.gov/pubmed/18299833 http://dx.doi.org/10.1007/s00277-008-0447-2

Ejemplares similares

Incidence of neutropenia, chemotherapy delivery, and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups
por: Pettengell, Ruth, et al.
Publicado: (2011)

Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2011)

Erratum to: Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma
por: Pettengell, Ruth, et al.
Publicado: (2012)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma
por: Terada, Yoshiki, et al.
Publicado: (2009)

Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP
por: Bewarder, Moritz, et al.
Publicado: (2023)

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14
por: Gutiérrez, Antonio, et al.
Publicado: (2015)

Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery
por: Schwenkglenks, Matthias, et al.
Publicado: (2010)

Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP
por: Doumas, Stergios, et al.
Publicado: (2013)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors
por: Pfeil, Alena M, et al.
Publicado: (2014)

Re: Estimating and reducing dose received by cardiac devices for patients undergoing radiotherapy
por: Mihailidis, Dimitris N.
Publicado: (2016)

Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017
por: Albertsson-Lindblad, Alexandra, et al.
Publicado: (2021)

The average relative dose intensity of R‐CHOP is an independent factor determining favorable overall survival in diffuse large B‐cell lymphoma patients
por: Długosz‐Danecka, Monika, et al.
Publicado: (2019)

Response to Re: Estimating and reducing dose received by cardiac devices for patients undergoing radiotherapy
por: Archambault, Louis, et al.
Publicado: (2016)

Enucleation of painful blind eye for refractory intraocular lymphoma after dose-limiting chemotherapy and radiotherapy
por: Chow, Prudence Po-chee, et al.
Publicado: (2012)

No sex differential in relative survival among older patients with DLBCL treated with R-CHOP21: a population-based study
por: Geerdes, Emma E., et al.
Publicado: (2023)

Impact of pegfilgrastim approval on relative dose intensity and outcomes of R-CHOP for diffuse large B-cell lymphoma
por: Morita, Yuka, et al.
Publicado: (2022)

What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness
por: Sekiguchi, Naohiro, et al.
Publicado: (2019)

Half stop and chop, petal by petal deflowering of hard cataracts
por: Dudani, Ajay I, et al.
Publicado: (2022)

High-dose chemotherapy with reduced-dose craniospinal radiotherapy in children with newly diagnosed high-risk brain tumor
por: Chung, Nack-Gyun
Publicado: (2010)

High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
por: Kusano, Y, et al.
Publicado: (2017)

Clinical Analysis of the HBV Infection Status of 135 Patients with Diffuse Large B Cell Lymphoma Treated with R-CHOP or CHOP/CHOP-Like Chemotherapy
por: Guo, Wei, et al.
Publicado: (2015)

Long‐term follow‐up after R‐High CHOP/CHASER/LEED with Auto‐PBSCT in untreated mantle cell lymphoma—Final analysis of JCOG0406
por: Ogura, Michinori, et al.
Publicado: (2023)

Patients with B-cell lymphoma receiving anti-CD20 monoclonal antibody-containing chemotherapies and seroreactive patterns in response to COVID-19 vaccination
por: Inaba, Tohru, et al.
Publicado: (2022)

An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy
por: Lu, Yaxiao, et al.
Publicado: (2021)

Patterns of mortality after prolonged follow-up of a randomised controlled trial using granulocyte colony-stimulating factor to maintain chemotherapy dose intensity in non-Hodgkin's lymphoma
por: Clamp, A R, et al.
Publicado: (2008)

Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma
por: Ratner, L, et al.
Publicado: (2016)

The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression
por: Wei, Xiaolei, et al.
Publicado: (2014)

Why Coverage of Influenza Vaccine Is Not Enough in Patients Receiving Chemotherapy?
por: Meidani, Mohsen, et al.
Publicado: (2011)

Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy
por: Fournier, Q., et al.
Publicado: (2017)

Cyclosporine, prednisone, and high-dose immunoglobulin treatment of angioimmunoblastic T-cell lymphoma refractory to prior CHOP or CHOP-like regimen
por: Chen, Xing-Gui, et al.
Publicado: (2011)

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
por: Aoki, T, et al.
Publicado: (2015)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study
por: Zhang, Mu‐Chen, et al.
Publicado: (2021)

Efficacy of oral levofloxacin monotherapy against low-risk FN in patients with malignant lymphoma who received chemotherapy using the CHOP regimen
por: Mogi, Ai, et al.
Publicado: (2020)

p21 is necessary for the beneficial effects of fasting during chemotherapy
por: Plaza, Adrián, et al.
Publicado: (2022)

Occurrence of sarcoidosis after chemotherapy for non-Hodgkin lymphoma
por: Cho, Hyungwoo, et al.
Publicado: (2016)

Intraocular lymphoma as relapse after chemotherapy for primary breast diffuse large B-cell lymphoma
por: Matsuo, Toshihiko, et al.
Publicado: (2018)

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis
por: Kessler, Chiara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04gmflgr9b5d3vcgq0fpv0iauc